Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A block of the sphenopalatine ganglion in chronic migraine (safety study)
2014-001852-43Phase 2Completed
- Sponsor
- Department of Neuromedicine and Movement Science, NTNU
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of botulinum toxin type A in chronic migraine, sponsored by Department of Neuromedicine and Movement Science, NTNU. Primary endpoint: Adverse events. Started Jun 2014; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2014-001852-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001852-43.